Canagliflozin for advanced solid tumors in patients with or without diabetes
Treatments studied
Part of Cancer clinical trials.
This trial tests canagliflozin, a diabetes drug, combined with immunotherapy for people with advanced solid tumors. It may help if you have type 2 diabetes or are at risk, but you don't need diabetes to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 80 years old.
- You have an advanced solid tumor that hasn't responded to standard treatment or for which no standard treatment exists, and your doctor thinks immunotherapy is an option.
- Your cancer can be measured on a CT scan.
- You are in fairly good health (ECOG score 0 or 1) and expected to live at least 3 months.
- You either have type 2 diabetes or no diabetes at all (but not type 1 diabetes).
- Your blood counts, kidney function, liver function, and heart function meet certain minimum levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an immunotherapy drug called GLS-012, alone and with another drug (GLS-010), in people with advanced solid cancers that have worsened despite standard treatment. It aims to see how well the treatment works and how safe it is, especially when given in different combinations.
This study tests a new drug (BGB-26808) alone or with another drug (tislelizumab) for people with advanced solid tumors that haven't responded to standard treatments. The goal is to see if the combination can help shrink tumors or slow their growth.
This trial tests if adding metformin, a common diabetes drug, to standard chemotherapy or immunotherapy can help treat advanced solid tumors. It may be an option for people who are already eligible for chemo or immunotherapy.
This trial tests a new combination of drugs (FC084CSA plus tislelizumab) for people with advanced solid tumors, especially lung cancer that has gotten worse after prior immunotherapy and chemotherapy. It may be an option if you've tried standard treatments and they no longer work.
This trial tests a single immunotherapy drug (tislelizumab) for people with advanced solid tumors that haven't responded to other treatments. It's for those who haven't had immunotherapy before and have a specific genetic marker in their tumor that suggests their immune system might be more active.
This trial tests a combination of two immunotherapy drugs (tiragolumab and atezolizumab) for people with advanced solid tumors that have stopped responding to standard treatments or cannot be treated with available therapies. It may be an option if your tumor has certain immune-related markers.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.